A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States

By afschroeder • October 10, 2025

Cummings AL, Sussell J, Rosettie KL, El Moustaid F, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States. Am J Clin Oncol. 2025 Oct 8. doi: 10.1097/COC.0000000000001248. Epub ahead of print. PMID: 41066159.

Tags: adjuvant treatment, Alectinib, anaplastic lymphoma kinase, Hematology/Oncology, Non-small cell lung cancer, platinum-based chemotherapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study

Timmerman J, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory GP, Keane C, Tzoran I, Vucinic V, Zinzani PL, West[...]

A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers

Fakih M, Doi T, Tolcher A, Hong D, Tie J, Messersmith W, Koyama T, Rosen L, Borlido J, Damore MA, Delioukina M, Cheronis I, Clark[...]

Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs)

Lowenstein LM, Bernal MP, Bergren EP, Busaidy TK, Brauer ER, Ganz PA, Smith GL, Shih YT. Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and[...]